Karen A Landmeier1, Monica Lanning2, David Carmody2, Siri Atma W Greeley2, Michael E Msall1. 1. Section Department of Developmental and Behavioral Pediatrics, The University of Chicago, Chicago, Illinois. 2. Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, The University of Chicago, Chicago, Illinois.
Abstract
OBJECTIVES: Mutations in KCNJ11 are the most common cause of permanent neonatal diabetes mellitus (NDM). Approximately 25% of patients have obvious neurological dysfunction, but whether milder related problems might be more common has been unclear. We sought to assess the prevalence of parental concerns about learning, behavior, attention deficit hyperactivity disorder (ADHD), social competency, and sleep in subjects with KCNJ11-related NDM compared to unaffected sibling controls. STUDY DESIGN: Subjects or their guardians in the University of Chicago Monogenic Diabetes Registry completed a survey examining learning, behavior, ADHD and sleep. Thirty subjects with KCNJ11 -related NDM and 25 unaffected sibling controls were assessed. Data were analyzed using GraphPad Prism 6. Nonparametric analysis was performed using Fisher's exact test for group comparisons. RESULTS: Thirteen (43%) individuals with KCNJ11 -related NDM had treatment for or a diagnosis of ADHD compared to two (8%) of the sibling controls (P < 0.05). Compared to their sibling controls, individuals with KCNJ11 mutations had significant differences in behavior difficulties, social awareness, academic achievement and the need for an Individualized Education Plan (IEP). As seen in other neurodevelopmental disorders, individuals with KCNJ11 mutations also had significantly higher rates of sleep difficulties (P < 0.01). CONCLUSION: Patients with KCNJ11 -related NDM are at an increased risk for delays in learning, social-emotional and behavioral development, ADHD and sleep difficulties based on parent report. Early identification, along with integrated medical and developmental support, may promote better neurodevelopmental outcomes for this unique population. Further investigation utilizing detailed neuropsychological testing will better define the neurodevelopmental consequences of KATP mutations.
OBJECTIVES: Mutations in KCNJ11 are the most common cause of permanent neonatal diabetes mellitus (NDM). Approximately 25% of patients have obvious neurological dysfunction, but whether milder related problems might be more common has been unclear. We sought to assess the prevalence of parental concerns about learning, behavior, attention deficit hyperactivity disorder (ADHD), social competency, and sleep in subjects with KCNJ11-related NDM compared to unaffected sibling controls. STUDY DESIGN: Subjects or their guardians in the University of Chicago Monogenic Diabetes Registry completed a survey examining learning, behavior, ADHD and sleep. Thirty subjects with KCNJ11 -related NDM and 25 unaffected sibling controls were assessed. Data were analyzed using GraphPad Prism 6. Nonparametric analysis was performed using Fisher's exact test for group comparisons. RESULTS: Thirteen (43%) individuals with KCNJ11 -related NDM had treatment for or a diagnosis of ADHD compared to two (8%) of the sibling controls (P < 0.05). Compared to their sibling controls, individuals with KCNJ11 mutations had significant differences in behavior difficulties, social awareness, academic achievement and the need for an Individualized Education Plan (IEP). As seen in other neurodevelopmental disorders, individuals with KCNJ11 mutations also had significantly higher rates of sleep difficulties (P < 0.01). CONCLUSION:Patients with KCNJ11 -related NDM are at an increased risk for delays in learning, social-emotional and behavioral development, ADHD and sleep difficulties based on parent report. Early identification, along with integrated medical and developmental support, may promote better neurodevelopmental outcomes for this unique population. Further investigation utilizing detailed neuropsychological testing will better define the neurodevelopmental consequences of KATP mutations.
Authors: Siri Atma W Greeley; Rochelle N Naylor; Lindsay S Cook; Susan E Tucker; Rebecca B Lipton; Louis H Philipson Journal: J Diabetes Sci Technol Date: 2011-07-01
Authors: Ewan R Pearson; Isabelle Flechtner; Pål R Njølstad; Maciej T Malecki; Sarah E Flanagan; Brian Larkin; Frances M Ashcroft; Iwar Klimes; Ethel Codner; Violeta Iotova; Annabelle S Slingerland; Julian Shield; Jean-Jacques Robert; Jens J Holst; Penny M Clark; Sian Ellard; Oddmund Søvik; Michel Polak; Andrew T Hattersley Journal: N Engl J Med Date: 2006-08-03 Impact factor: 91.245
Authors: Rebecca H Clark; James S McTaggart; Richard Webster; Roope Mannikko; Michaela Iberl; Xiu Li Sim; Patrik Rorsman; Maike Glitsch; David Beeson; Frances M Ashcroft Journal: Science Date: 2010-07-01 Impact factor: 47.728
Authors: D Iafusco; O Massa; B Pasquino; C Colombo; L Iughetti; C Bizzarri; C Mammì; D Lo Presti; T Suprani; R Schiaffini; Colin G Nichols; L Russo; V Grasso; F Meschi; R Bonfanti; S Brescianini; F Barbetti Journal: Acta Diabetol Date: 2011-09-28 Impact factor: 4.280
Authors: Elisa De Franco; Sarah E Flanagan; Jayne A L Houghton; Hana Lango Allen; Deborah J G Mackay; I Karen Temple; Sian Ellard; Andrew T Hattersley Journal: Lancet Date: 2015-07-28 Impact factor: 79.321
Authors: Hanna Hong; Rory Kamerman-Kretzmer; Roberta Kato; Tena Rosser; Michele VanHirtum-Das; Sally L Davidson Ward Journal: J Clin Sleep Med Date: 2018-08-15 Impact factor: 4.062
Authors: Monica S Lanning; David Carmody; Łukasz Szczerbiński; Lisa R Letourneau; Rochelle N Naylor; Siri Atma W Greeley Journal: Pediatr Diabetes Date: 2017-12-05 Impact factor: 4.866
Authors: Pamela Bowman; Jacob Day; Lorna Torrens; Maggie H Shepherd; Bridget A Knight; Tamsin J Ford; Sarah E Flanagan; Ali Chakera; Andrew T Hattersley; Adam Zeman Journal: Diabetes Care Date: 2018-10-30 Impact factor: 19.112